Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2022
2021

May 12 2022

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Read More +

May 9 2022

MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab

Read More +

Apr 5 2022

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Read More +

Mar 24 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

Read More +

Oct 4 2021

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

Read More +

Aug 10 2021

MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors

Read More +

Jul 1 2021

MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO

Read More +

May 6 2021

MoonLake Immunotherapeutics announces publication in The Lancet

Read More +

May 3 2021

MoonLake In-licensing and launch

Read More +

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics AG Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2022 - MoonLake Immunotherapeutics

Privacy Policy